STE Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of 13.18% compared to STERIS Plc (Ireland)'s net margin of 14.91%. STERIS Plc (Ireland)'s return on equity of 10.26% beat Boston Scientific Corp.'s return on equity of 12.46%.

STERIS Plc (Ireland) has a consensus price target of $281.63, signalling upside risk potential of 9.66%. On the other hand Boston Scientific Corp. has an analysts' consensus of $125.45 which suggests that it could grow by 28.48%. Given that Boston Scientific Corp. has higher upside potential than STERIS Plc (Ireland), analysts believe Boston Scientific Corp. is more attractive than STERIS Plc (Ireland).

STERIS Plc (Ireland) has a beta of 1.029, which suggesting that the stock is 2.924% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 33.029%.

STERIS Plc (Ireland) has a quarterly dividend of $0.63 per share corresponding to a yield of 0.94%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. STERIS Plc (Ireland) pays 35.14% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend. STERIS Plc (Ireland)'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

STERIS Plc (Ireland) quarterly revenues are $1.5B, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. STERIS Plc (Ireland)'s net income of $192.5M is lower than Boston Scientific Corp.'s net income of $755M. Notably, STERIS Plc (Ireland)'s price-to-earnings ratio is 36.56x while Boston Scientific Corp.'s PE ratio is 52.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for STERIS Plc (Ireland) is 4.45x versus 7.53x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Medtronic Plc has a net margin of 13.18% compared to STERIS Plc (Ireland)'s net margin of 15.42%. STERIS Plc (Ireland)'s return on equity of 10.26% beat Medtronic Plc's return on equity of 9.84%.

STERIS Plc (Ireland) has a consensus price target of $281.63, signalling upside risk potential of 9.66%. On the other hand Medtronic Plc has an analysts' consensus of $111.10 which suggests that it could grow by 13.91%. Given that Medtronic Plc has higher upside potential than STERIS Plc (Ireland), analysts believe Medtronic Plc is more attractive than STERIS Plc (Ireland).

STERIS Plc (Ireland) has a beta of 1.029, which suggesting that the stock is 2.924% more volatile than S&P 500. In comparison Medtronic Plc has a beta of 0.715, suggesting its less volatile than the S&P 500 by 28.513%.

STERIS Plc (Ireland) has a quarterly dividend of $0.63 per share corresponding to a yield of 0.94%. Medtronic Plc offers a yield of 2.9% to investors and pays a quarterly dividend of $0.71 per share. STERIS Plc (Ireland) pays 35.14% of its earnings as a dividend. Medtronic Plc pays out 77.47% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

STERIS Plc (Ireland) quarterly revenues are $1.5B, which are smaller than Medtronic Plc quarterly revenues of $9B. STERIS Plc (Ireland)'s net income of $192.5M is lower than Medtronic Plc's net income of $1.4B. Notably, STERIS Plc (Ireland)'s price-to-earnings ratio is 36.56x while Medtronic Plc's PE ratio is 26.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for STERIS Plc (Ireland) is 4.45x versus 3.61x for Medtronic Plc. Usually stocks with elevated PS ratios are considered overvalued.

Nutriband, Inc. has a net margin of 13.18% compared to STERIS Plc (Ireland)'s net margin of -1118.87%. STERIS Plc (Ireland)'s return on equity of 10.26% beat Nutriband, Inc.'s return on equity of -164.64%.

STERIS Plc (Ireland) has a consensus price target of $281.63, signalling upside risk potential of 9.66%. On the other hand Nutriband, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 243.25%. Given that Nutriband, Inc. has higher upside potential than STERIS Plc (Ireland), analysts believe Nutriband, Inc. is more attractive than STERIS Plc (Ireland).

STERIS Plc (Ireland) has a beta of 1.029, which suggesting that the stock is 2.924% more volatile than S&P 500. In comparison Nutriband, Inc. has a beta of 1.840, suggesting its more volatile than the S&P 500 by 84.015%.

STERIS Plc (Ireland) has a quarterly dividend of $0.63 per share corresponding to a yield of 0.94%. Nutriband, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. STERIS Plc (Ireland) pays 35.14% of its earnings as a dividend. Nutriband, Inc. pays out -- of its earnings as a dividend. STERIS Plc (Ireland)'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

STERIS Plc (Ireland) quarterly revenues are $1.5B, which are larger than Nutriband, Inc. quarterly revenues of $346.1K. STERIS Plc (Ireland)'s net income of $192.5M is higher than Nutriband, Inc.'s net income of -$3.9M. Notably, STERIS Plc (Ireland)'s price-to-earnings ratio is 36.56x while Nutriband, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for STERIS Plc (Ireland) is 4.45x versus 21.81x for Nutriband, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Zimmer Biomet Holdings, Inc. has a net margin of 13.18% compared to STERIS Plc (Ireland)'s net margin of 11.55%. STERIS Plc (Ireland)'s return on equity of 10.26% beat Zimmer Biomet Holdings, Inc.'s return on equity of 6.45%.

STERIS Plc (Ireland) has a consensus price target of $281.63, signalling upside risk potential of 9.66%. On the other hand Zimmer Biomet Holdings, Inc. has an analysts' consensus of $102.61 which suggests that it could grow by 10.51%. Given that Zimmer Biomet Holdings, Inc. has higher upside potential than STERIS Plc (Ireland), analysts believe Zimmer Biomet Holdings, Inc. is more attractive than STERIS Plc (Ireland).

STERIS Plc (Ireland) has a beta of 1.029, which suggesting that the stock is 2.924% more volatile than S&P 500. In comparison Zimmer Biomet Holdings, Inc. has a beta of 0.616, suggesting its less volatile than the S&P 500 by 38.41%.

STERIS Plc (Ireland) has a quarterly dividend of $0.63 per share corresponding to a yield of 0.94%. Zimmer Biomet Holdings, Inc. offers a yield of 1.03% to investors and pays a quarterly dividend of $0.24 per share. STERIS Plc (Ireland) pays 35.14% of its earnings as a dividend. Zimmer Biomet Holdings, Inc. pays out 21.66% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

STERIS Plc (Ireland) quarterly revenues are $1.5B, which are smaller than Zimmer Biomet Holdings, Inc. quarterly revenues of $2B. STERIS Plc (Ireland)'s net income of $192.5M is lower than Zimmer Biomet Holdings, Inc.'s net income of $231.2M. Notably, STERIS Plc (Ireland)'s price-to-earnings ratio is 36.56x while Zimmer Biomet Holdings, Inc.'s PE ratio is 22.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for STERIS Plc (Ireland) is 4.45x versus 2.31x for Zimmer Biomet Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.